Hief C, Podczeck A, Frohner K, Nürnberg M, Kaltenbrunner W, Steinbach K
III. Medizinischen Abteilung mit Kardiologie, Ludwig-Boltzmann-Institut für Arrhythmieforschung, Wilhelminenspitals, Wien.
Wien Med Wochenschr. 1994;144(14-15):379-81.
The incidence of avoidable or unavoidable, cardial and extracardial side effects is a risk in the drug treatment of supraventricular and ventricular tachyarrhythmias. Therefore the indication of antiarrhythmic drug therapy has to be considered critically. The patient has to be controlled close-meshed, especially at the beginning of the drug treatment. In patients with life threatening ventricular tachyarrhythmias, which can not be suppressed by drug therapy, nonpharmacological therapy--implantable cardioverter/defibrillator, catheterablation and heart-transplantation--has to be discussed.
在室上性和室性快速心律失常的药物治疗中，发生可避免或不可避免的心脏及心外副作用是一种风险。因此，必须审慎考虑抗心律失常药物治疗的适应症。必须对患者进行密切监测，尤其是在药物治疗开始时。对于药物治疗无法抑制的危及生命的室性快速心律失常患者，必须讨论非药物治疗——植入式心脏复律除颤器、导管消融和心脏移植。
